Dianox
Dianox develops DNA and RNA therapeutics to address proteins that are difficult to target with small molecules or antibodies. The company uses an AI-driven drug discovery platform combining proprietary deep learning models and the company’s large drug library to design novel nucleic acid drugs and optimize delivery. Dianox operates as a biotech R&D platform (B2B biotech) working with pharmaceutical and research partners across oncology, dermatology, and ophthalmology. Its technology stack centers on deep learning for molecular design, nucleic acid therapeutics (DNA and RNA), and delivery-focused development. The company is founder-led and focuses on advancing therapeutics and diagnostics for previously unreachable protein targets.
Dianox
Dianox develops DNA and RNA therapeutics to address proteins that are difficult to target with small molecules or antibodies. The company uses an AI-driven drug discovery platform combining proprietary deep learning models and the company’s large drug library to design novel nucleic acid drugs and optimize delivery. Dianox operates as a biotech R&D platform (B2B biotech) working with pharmaceutical and research partners across oncology, dermatology, and ophthalmology. Its technology stack centers on deep learning for molecular design, nucleic acid therapeutics (DNA and RNA), and delivery-focused development. The company is founder-led and focuses on advancing therapeutics and diagnostics for previously unreachable protein targets.